BridgeBio Pharma (BBIO) Gets a Buy Rating from Leerink Partners

In a report issued on October 12, Mani Foroohar from Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIOResearch Report). The company’s shares closed last Wednesday at $48.55.

According to TipRanks.com, Foroohar has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -18.1% and a 36.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and Adverum Biotechnologies.

BridgeBio Pharma has an analyst consensus of Strong Buy, with a price target consensus of $82.75, a 77.4% upside from current levels. In a report issued on October 3, BTIG also maintained a Buy rating on the stock with a $91.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BridgeBio Pharma’s market cap is currently $7.27B and has a P/E ratio of -12.20. The company has a Price to Book ratio of -15.04.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BBIO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.